Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria D Cappellini

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 14, 2012
Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trialCaterina Mariotti, Roberto Fancellu, Serena Caldarazzo, et al.
Orphanet Journal of Rare Diseases|January 3, 2012
Congenital dyserythropoietic anemia type II: molecular analysis and expression of the SEC23B geneFrancesca Punzo, Aida M Bertoli-Avella, Saverio Scianguetta, et al.
Ophthalmology|December 10, 2013
The spectrum of ocular alterations in patients with β-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticumGiulio Barteselli, Laura Dell'arti, Robert P Finger, et al.
Plos One|February 22, 2018
Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessmentCamilla Torlasco, Elena Cassinerio, Alberto Roghi, et al.
European Journal of Endocrinology|October 13, 2009
The pituitary-adrenal axis in adult thalassaemic patientsMassimo Scacchi, Leila Danesi, Agnese Cattaneo, et al.
Blood|December 25, 2009
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE studyAli T Taher, Khaled M Musallam, Mehran Karimi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 25, 2013
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in ratsChia Chi Sun, Valentina Vaja, Shanzhuo Chen, et al.
Current Medical Research and Opinion|May 30, 2008
Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA studyLuciana Scalone, Lorenzo G Mantovani, Marieke Krol, et al.
American Journal of Hematology|April 21, 2020
SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experienceIrene Motta, Margherita Migone De Amicis, Valeria M Pinto, et al.
Haematologica|September 18, 2012
Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset β-thalassemia majorCornelis L Harteveld, Chiara Refaldi, Antonino Giambona, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Movement Disorders : Official Journal of the Movement Disorder Society|March 14, 2012
Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trialCaterina Mariotti, Roberto Fancellu, Serena Caldarazzo, et al.
Orphanet Journal of Rare Diseases|January 3, 2012
Congenital dyserythropoietic anemia type II: molecular analysis and expression of the SEC23B geneFrancesca Punzo, Aida M Bertoli-Avella, Saverio Scianguetta, et al.
Ophthalmology|December 10, 2013
The spectrum of ocular alterations in patients with β-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticumGiulio Barteselli, Laura Dell'arti, Robert P Finger, et al.
Plos One|February 22, 2018
Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessmentCamilla Torlasco, Elena Cassinerio, Alberto Roghi, et al.
European Journal of Endocrinology|October 13, 2009
The pituitary-adrenal axis in adult thalassaemic patientsMassimo Scacchi, Leila Danesi, Agnese Cattaneo, et al.
Blood|December 25, 2009
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE studyAli T Taher, Khaled M Musallam, Mehran Karimi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 25, 2013
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in ratsChia Chi Sun, Valentina Vaja, Shanzhuo Chen, et al.
Current Medical Research and Opinion|May 30, 2008
Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA studyLuciana Scalone, Lorenzo G Mantovani, Marieke Krol, et al.
American Journal of Hematology|April 21, 2020
SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experienceIrene Motta, Margherita Migone De Amicis, Valeria M Pinto, et al.
Haematologica|September 18, 2012
Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset β-thalassemia majorCornelis L Harteveld, Chiara Refaldi, Antonino Giambona, et al.
Pageof 6